YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY)
Pancreatic Ductal Adenocarcinoma
Eucure (Beijing) Biopharma Co., Ltdmonoclonal_antibodyPhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 65/ 100
Competitive context
282 Active assets in the Pancreatic Ductal Adenocarcinoma cohort.
View all 50 →
Same molecule, other indications
YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →